Bronchial Thermoplasty Catheters

Global Bronchial Thermoplasty Catheters Market to Reach US$4.6 Billion by 2030

The global market for Bronchial Thermoplasty Catheters estimated at US$3.8 Billion in the year 2024, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Hospitals, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Ambulatory Surgery Centers segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 5.9% CAGR

The Bronchial Thermoplasty Catheters market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$904.4 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Bronchial Thermoplasty Catheters Market – Key Trends & Drivers Summarized

Why Are Bronchial Thermoplasty Catheters Gaining Traction as a Minimally Invasive Solution for Severe Asthma Management?
Bronchial thermoplasty catheters are emerging as a specialized intervention for patients with severe, persistent asthma that remains uncontrolled despite maximal inhaled therapy. These devices deliver controlled thermal energy to the airway wall to reduce excess smooth muscle tissue—resulting in decreased bronchoconstriction, improved airflow, and reduced asthma exacerbations. As global asthma prevalence continues to rise and traditional pharmacologic options prove inadequate for a subset of patients, bronchial thermoplasty is gaining clinical traction as a long-term, procedure-based therapy for disease control.

This non-pharmacologic, minimally invasive treatment aligns with the shift toward personalized, intervention-based chronic respiratory care. Supported by clinical evidence demonstrating reductions in emergency room visits, hospitalization rates, and steroid dependency, bronchial thermoplasty catheters offer a therapeutic alternative for high-risk patients who are not candidates for or do not respond adequately to biologics. The procedure’s one-time intervention model also appeals to payers and health systems aiming to reduce long-term disease management costs.

How Are Device Advancements and Procedural Standardization Improving Adoption of Bronchial Thermoplasty?
Advancements in catheter design, energy control algorithms, and bronchoscopic delivery systems are enhancing procedural safety, precision, and operator confidence. Modern bronchial thermoplasty catheters feature flexible, tapered designs with electrode arrays that conform to airway anatomy and deliver uniform radiofrequency energy while minimizing mucosal trauma. Real-time temperature monitoring, safety interlocks, and dose-limiting protocols further reduce complications and support reproducible outcomes across treatment sessions.

Training programs, procedural checklists, and standardized patient selection criteria are streamlining clinical workflows and improving treatment consistency. Integration with advanced bronchoscopes and imaging systems is enabling improved visualization, navigation, and lesion targeting. These improvements are making the procedure more accessible to interventional pulmonologists and supporting wider clinical acceptance in academic, hospital, and specialty care environments.

Where Is Demand for Bronchial Thermoplasty Catheters Increasing and Which Patient Populations Are Driving Utilization?
North America remains the leading market for bronchial thermoplasty, driven by early FDA approval, reimbursement coverage in select U.S. regions, and strong specialist infrastructure. Europe follows with steady adoption in countries such as Germany, France, and the U.K., where healthcare systems are integrating bronchial thermoplasty into severe asthma management guidelines. Asia-Pacific is seeing emerging interest, particularly in Japan, South Korea, and Australia, where clinical awareness and asthma prevalence are high.

Primary patient populations include adults with severe, refractory asthma not controlled by high-dose inhaled corticosteroids and long-acting beta-agonists, and who have frequent exacerbations or corticosteroid dependence. Bronchial thermoplasty is also considered for patients with contraindications to long-term biologic therapy or poor adherence to daily inhaler regimens. Payers and clinicians are increasingly targeting this intervention toward patients with high healthcare utilization or poor quality-of-life metrics—seeking both symptom control and cost mitigation.

What Is Fueling the Global Growth of the Bronchial Thermoplasty Catheters Market?
The global bronchial thermoplasty catheter market is being driven by the rising clinical burden of severe asthma, growing limitations of conventional therapies, and increasing healthcare interest in interventional, cost-effective disease management approaches. As asthma-related hospitalizations and systemic steroid use remain significant public health concerns, bronchial thermoplasty offers a one-time procedural solution with demonstrated long-term benefits.

Supportive clinical trial data, growing physician familiarity, and expanding insurance coverage are reinforcing adoption, particularly in specialized pulmonary centers. Ongoing technological refinements, combined with patient education and multidisciplinary asthma management programs, are further improving outcomes and acceptance. As global respiratory care pivots toward precision and procedure-based intervention, a defining question shapes the future of this niche segment: Can bronchial thermoplasty catheters continue to demonstrate durable efficacy, procedural scalability, and payer-aligned value—while establishing a stable foothold in the broader therapeutic landscape for severe asthma?

SCOPE OF STUDY:

The report analyzes the Bronchial Thermoplasty Catheters market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
End-User (Hospitals, Ambulatory Surgery Centers)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories
• AngioDynamics, Inc.
• Becton, Dickinson & Co.
• Boehringer Ingelheim
• Boston Scientific Corp.
• C. R. Bard, Inc.
• CONMED Corporation
• Cook Medical LLC
• Johnson & Johnson
• Karl Storz GmbH & Co. KG
• Medtronic plc
• Merit Medical Systems
• Neomedic International
• Olympus Corporation
• Penumbra, Inc.
• Pulmonx Corporation
• Smith & Nephew plc
• Stryker Corporation
• Teleflex Incorporated
• Terumo Corporation

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.